OBJECTIVE: This study compared the acute phase (12-week) efficacy of fluoxetine versus placebo for the treatment of the depressive symptoms and the drinking of adolescents with comorbid major depression (MDD) and an alcohol use disorder (AUD). We hypothesized that fluoxetine would demonstrate efficacy versus placebo for the treatment of both the depressive symptoms and the drinking of comorbid MDD/AUD adolescents. METHODS: We conducted the first double-blind placebo-controlled study of fluoxetine in adolescents with comorbid MDD/AUD. All participants in both treatment groups also received intensive manual-based Cognitive Behavioral Therapy (CBT) and Motivation Enhancement Therapy (MET). RESULTS:Fluoxetine was well tolerated in this treatment population. No significant group-by-time interactions were noted for any depression-related or drinking-related outcome variable. Subjects in both the fluoxetine group and the placebo group showed significant within-group improvement in both depressive symptoms and level of alcohol consumption. End-of-study levels of depression and drinking were low in both treatment groups. CONCLUSIONS: The lack of a significant between-group difference in depressive symptoms and in drinking may reflect limited medication efficacy, or may result from limited sample size or from efficacy of the CBT/MET psychotherapy. Large multi-site studies are warranted to further clarify the efficacy of SSRI medications in this adolescent MDD/AUD population.
RCT Entities:
OBJECTIVE: This study compared the acute phase (12-week) efficacy of fluoxetine versus placebo for the treatment of the depressive symptoms and the drinking of adolescents with comorbid major depression (MDD) and an alcohol use disorder (AUD). We hypothesized that fluoxetine would demonstrate efficacy versus placebo for the treatment of both the depressive symptoms and the drinking of comorbid MDD/AUD adolescents. METHODS: We conducted the first double-blind placebo-controlled study of fluoxetine in adolescents with comorbid MDD/AUD. All participants in both treatment groups also received intensive manual-based Cognitive Behavioral Therapy (CBT) and Motivation Enhancement Therapy (MET). RESULTS:Fluoxetine was well tolerated in this treatment population. No significant group-by-time interactions were noted for any depression-related or drinking-related outcome variable. Subjects in both the fluoxetine group and the placebo group showed significant within-group improvement in both depressive symptoms and level of alcohol consumption. End-of-study levels of depression and drinking were low in both treatment groups. CONCLUSIONS: The lack of a significant between-group difference in depressive symptoms and in drinking may reflect limited medication efficacy, or may result from limited sample size or from efficacy of the CBT/MET psychotherapy. Large multi-site studies are warranted to further clarify the efficacy of SSRI medications in this adolescent MDD/AUD population.
Authors: Jack R Cornelius; Duncan B Clark; Oscar G Bukstein; Boris Birmaher; Ihsan M Salloum; Sandra A Brown Journal: Addict Behav Date: 2005-08-15 Impact factor: 3.913
Authors: Paula D Riggs; Susan K Mikulich-Gilbertson; Robert D Davies; Michelle Lohman; Constance Klein; Shannon K Stover Journal: Arch Pediatr Adolesc Med Date: 2007-11
Authors: Graham J Emslie; Beth D Kennard; Taryn L Mayes; Jeanne Nightingale-Teresi; Thomas Carmody; Carroll W Hughes; A John Rush; Rongrong Tao; Jeanne W Rintelmann Journal: Am J Psychiatry Date: 2008-02-15 Impact factor: 18.112
Authors: John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe Journal: JAMA Date: 2004-08-18 Impact factor: 56.272
Authors: Jack R Cornelius; Oscar G Bukstein; Ihsan M Salloum; Thomas M Kelly; D Scott Wood; Duncan B Clark Journal: J Child Adolesc Psychopharmacol Date: 2004 Impact factor: 2.576
Authors: Mary Clair-Michaud; Rosemarie A Martin; Linda A R Stein; Shayna Bassett; Rebecca Lebeau; Charles Golembeske Journal: J Subst Abuse Treat Date: 2015-09-25
Authors: Jack R Cornelius; Tammy Chung; Antoine B Douaihy; Levent Kirisci; Jody Glance; Julie Kmiec; Douglas FitzGerald; Maribeth A Wesesky; Ihsan Salloum Journal: Psychiatry Res Date: 2016-06-15 Impact factor: 3.222
Authors: Jack R Cornelius; Oscar G Bukstein; Antoine B Douaihy; Duncan B Clark; Tammy A Chung; Dennis C Daley; D Scott Wood; Sandra J Brown Journal: Drug Alcohol Depend Date: 2010-06-23 Impact factor: 4.492
Authors: Matthew E Hirschtritt; Maria E Pagano; Kelly M Christian; Nora K McNamara; Robert J Stansbrey; Jacqui Lingler; Jon E Faber; Christine A Demeter; Denise Bedoya; Robert L Findling Journal: J Subst Abuse Treat Date: 2011-11-23